Effects of Tocilizumab on Inflammation and Iron Metabolism in Critically Ill Patients with COVID-19
Effects of Tocilizumab on Inflammation and Iron Metabolism in Critically Ill Patients with COVID-19
About this item
Full title
Author / Creator
Publisher
Switzerland: MDPI AG
Journal title
Language
English
Formats
Publication information
Publisher
Switzerland: MDPI AG
Subjects
More information
Scope and Contents
Contents
COVID-19 produces cytokine-mediated persistent inflammation and is associated with elevated iron stores and low circulating iron. It is believed that central to the pathophysiological mechanism is interleukin 6 and hepcidin. A state of iron overload, termed hyperferritinemia, and inflammatory anemia take place. Both conditions are linked to a worse...
Alternative Titles
Full title
Effects of Tocilizumab on Inflammation and Iron Metabolism in Critically Ill Patients with COVID-19
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_70b918936a44446098dee3c1e6d55395
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_70b918936a44446098dee3c1e6d55395
Other Identifiers
ISSN
1999-4923
E-ISSN
1999-4923
DOI
10.3390/pharmaceutics15020646
